Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This 4 month, open-label study will evaluate the safety and tolerability of fingolimod 0.5 mg
in patients with relapsing-remitting multiple sclerosis (RRMS) and generate additional data
in Multiple Sclerosis (MS) patient population that closely resembles the clinical population
seen in routine medical care.